Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 to 75 years old at the time of signing the consent form
• People who have been diagnosed with non-small cell lung cancer (NSCLC) confirmed by a laboratory test of tissue or cell samples
• People who have not had any previous systemic (whole-body) treatment for their cancer
• People who have not had any previous local treatment (such as surgery or radiation) for their NSCLC
• People whose lung cancer has a specific gene change called an EGFR sensitizing mutation, confirmed by lab testing
• People who are generally well enough to carry out light activity, as measured by a standard health scoring scale (ECOG score of 0 or 1), assessed within 7 days before joining the trial
• People who have at least one measurable area of cancer that can be tracked during the trial
• People with a life expectancy of at least 24 weeks
• People whose organs (such as kidneys and liver) and bone marrow are functioning well enough, as determined by the trial team
• Women who could become pregnant, and men whose partners could become pregnant, who agree to use effective contraception from signing the consent form until 6 months after the last dose
• People who are willing to join voluntarily, sign the consent form, and are able to attend the required visits and follow the trial procedures

Who may not be able to join:

• People whose lung cancer includes certain other cancer types in the same tumour, such as small cell lung cancer, neuroendocrine carcinoma, carcinosarcoma, or more than 10% squamous cell carcinoma
• People who have had another type of cancer within the 3 years before joining the trial
• People whose resting heart trace (ECG) shows results that the trial team considers clinically significant
• People with certain heart or blood vessel conditions or related risk factors (confirm with trial site for full details)
• People with other serious ongoing health conditions that are not well controlled, as judged by the trial doctor
• People with a history of, or current, lung inflammation conditions such as interstitial lung disease or non-infectious pneumonitis (including cases caused by previous medications)
• People with serious lung damage caused by complications of a lung condition
• People who have taken corticosteroid medications (such as prednisone) at doses above 10 mg per day, or other immune-suppressing medications, within the 2 weeks before joining the trial
• People with known active tuberculosis affecting the lungs
• People who have previously received an organ transplant or a stem cell transplant from another person
• People with active hepatitis B infection
• People who test positive for HIV, have a history of AIDS, or have a known active syphilis infection
• People with a known allergy or serious sensitivity to the study drugs (osimertinib or sacituzumab tirumotecan) or any of their ingredients, including polysorbate-20, or who have had a severe allergic reaction to other biological medicines
• People who have received a live vaccine within 30 days before joining the trial, or who plan to receive one during the trial
• Women who are pregnant or breastfeeding
• People with any other condition that the trial doctor believes could affect the safety of the participant or the reliability of the trial results

Important: Always verify eligibility with the trial site directly before applying.